Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2019

Open Access 01-12-2019 | Research

Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture

Authors: Niu Li, Yufei Xu, Yi Zhang, Guoqiang Li, Tingting Yu, Ruen Yao, YunFang Zhou, Yiping Shen, Lei Yin, Xiumin Wang, Jian Wang

Published in: Orphanet Journal of Rare Diseases | Issue 1/2019

Login to get access

Abstract

Background

Gain-of-function pathogenic variants of the Erb-B2 receptor tyrosine kinase 3 (ERBB3) gene contribute to the occurrence and development of a variety of human carcinomas through activation of phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK) signaling. ERBB3 gene homozygous germline variants, whose loss of function may cause autosomal recessive congenital contractural syndrome, were recently identified. This study aims to identify the disease-causing gene in a Chinese pedigree with variable phenotypes involving multiple systems, including developmental delay, postnatal growth retardation, transient lower limb asymmetry, facial malformations, atrioventricular canal malformation, bilateral nystagmus and amblyopia, feeding difficulties, immunodeficiency, anemia, and liver damage, but without congenital contracture.

Methods

Trio-whole exome sequencing (WES) was performed to identify the disease-causing gene in a 24-month-old Chinese female patient. The pathogenicity of the identified variants was evaluated using in silico tools and in vitro functional studies.

Results

Trio-WES revealed compound heterozygous variants of c.1253 T > C (p.I418T) and c.3182dupA (p.N1061Kfs*16) in the ERBB3 gene. Functional studies showed that p.I418T resulted in normal expression of ERBB3, which was capable of interacting with ERBB2. However, the variant impaired ERBB3 phosphorylation, consequently blocking ERBB2 phosphorylation and AKT and ERK activation. The truncated protein resulting from the c.3182dupA variant also lacked the capacity to activate downstream signaling pathways.

Conclusions

We report the first patient with a novel multisystem syndrome disorder without congenital contracture resulting from biallelic loss-of-function variants of ERBB3.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lee H, Akita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 2001;61:4467–73.PubMed Lee H, Akita RW, Sliwkowski MX, Maihle NJ. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 2001;61:4467–73.PubMed
2.
go back to reference Humtsoe JO, Pham E, Louie RJ, Chan DA, Kramer RH. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth. Oncogene. 2016;35:1554–64.CrossRef Humtsoe JO, Pham E, Louie RJ, Chan DA, Kramer RH. ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth. Oncogene. 2016;35:1554–64.CrossRef
3.
go back to reference Ieguchi K, Fujita M, Ma Z, Davari P, Taniguchi Y, Sekiguchi K, et al. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha} v {beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling. J Biol Chem. 2010;285:31388–98.CrossRef Ieguchi K, Fujita M, Ma Z, Davari P, Taniguchi Y, Sekiguchi K, et al. Direct binding of the EGF-like domain of neuregulin-1 to integrins ({alpha} v {beta}3 and {alpha}6{beta}4) is involved in neuregulin-1/ErbB signaling. J Biol Chem. 2010;285:31388–98.CrossRef
4.
go back to reference Steinkamp MP, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol. 2014;34:965–77.CrossRef Steinkamp MP, Low-Nam ST, Yang S, Lidke KA, Lidke DS, Wilson BS. erbB3 is an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol. 2014;34:965–77.CrossRef
5.
go back to reference Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603–17.CrossRef Jaiswal BS, Kljavin NM, Stawiski EW, Chan E, Parikh C, Durinck S, et al. Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013;23:603–17.CrossRef
6.
go back to reference Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872–6.CrossRef Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet. 2014;46:872–6.CrossRef
7.
go back to reference Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–48.CrossRef Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15:413–48.CrossRef
8.
go back to reference Braunstein EM, Li R, Sobreira N, Marosy B, Hetrick K, Doheny K, et al. A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. Leukemia. 2016;30:2242–5.CrossRef Braunstein EM, Li R, Sobreira N, Marosy B, Hetrick K, Doheny K, et al. A germline ERBB3 variant is a candidate for predisposition to erythroid MDS/erythroleukemia. Leukemia. 2016;30:2242–5.CrossRef
9.
go back to reference Landau D, Mishori-Dery A, Hershkovitz R, Narkis G, Elbedour K, Carmi R. A new autosomal recessive congenital contractural syndrome in an Israeli Bedouin kindred. Am J Med Genet A. 2003;117A:37–40.CrossRef Landau D, Mishori-Dery A, Hershkovitz R, Narkis G, Elbedour K, Carmi R. A new autosomal recessive congenital contractural syndrome in an Israeli Bedouin kindred. Am J Med Genet A. 2003;117A:37–40.CrossRef
10.
go back to reference Narkis G, Landau D, Manor E, Elbedour K, Tzemach A, Fishelson M, et al. Homozygosity mapping of lethal congenital contractural syndrome type 2 (LCCS2) to a 6 cM interval on chromosome 12q13. Am J Med Genet A. 2004;130A:272–6.CrossRef Narkis G, Landau D, Manor E, Elbedour K, Tzemach A, Fishelson M, et al. Homozygosity mapping of lethal congenital contractural syndrome type 2 (LCCS2) to a 6 cM interval on chromosome 12q13. Am J Med Genet A. 2004;130A:272–6.CrossRef
11.
go back to reference Narkis G, Ofir R, Manor E, Landau D, Elbedour K, Birk OS. Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway. Am J Hum Genet. 2007;81:589–95.CrossRef Narkis G, Ofir R, Manor E, Landau D, Elbedour K, Birk OS. Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway. Am J Hum Genet. 2007;81:589–95.CrossRef
12.
go back to reference Alfares A, Alfadhel M, Wani T, Alsahli S, Alluhaydan I, Al MF. A multicenter clinical exome study in unselected cohorts from a consanguineous population of Saudi Arabia demonstrated a high diagnostic yield. Mol Genet Metab. 2017;121:91–5.CrossRef Alfares A, Alfadhel M, Wani T, Alsahli S, Alluhaydan I, Al MF. A multicenter clinical exome study in unselected cohorts from a consanguineous population of Saudi Arabia demonstrated a high diagnostic yield. Mol Genet Metab. 2017;121:91–5.CrossRef
13.
go back to reference Yu T, Li J, Li N, Liu R, Ding Y. Chang get al. Obesity and developmental delay in a patient with uniparental disomy of chromosome 2. Int J Obes. 2016;40:1935–41.CrossRef Yu T, Li J, Li N, Liu R, Ding Y. Chang get al. Obesity and developmental delay in a patient with uniparental disomy of chromosome 2. Int J Obes. 2016;40:1935–41.CrossRef
14.
go back to reference Li J, Shi L, Zhang K, Zhang Y, Hu S, Zhao T, et al. VarCards: an integrated genetic and clinical database for coding variants in the human genome. Nucleic Acids Res. 2018;46:D1039–48.CrossRef Li J, Shi L, Zhang K, Zhang Y, Hu S, Zhao T, et al. VarCards: an integrated genetic and clinical database for coding variants in the human genome. Nucleic Acids Res. 2018;46:D1039–48.CrossRef
15.
go back to reference Li N, Chang G, Xu Y, Ding Y, Li G, Yu T, et al. Biallelic mutations in GPD1 gene in a Chinese boy mainly presented with obesity, insulin resistance, fatty liver, and short stature. Am J Med Genet A. 2017;173:3189–94.CrossRef Li N, Chang G, Xu Y, Ding Y, Li G, Yu T, et al. Biallelic mutations in GPD1 gene in a Chinese boy mainly presented with obesity, insulin resistance, fatty liver, and short stature. Am J Med Genet A. 2017;173:3189–94.CrossRef
17.
go back to reference Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68:1024–33.CrossRef Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68:1024–33.CrossRef
18.
go back to reference Carraway KL, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell. 1994;78:5–8.CrossRef Carraway KL, Cantley LC. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell. 1994;78:5–8.CrossRef
19.
go back to reference Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995;10:1813–21.PubMed Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995;10:1813–21.PubMed
20.
go back to reference Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100:8933–8.CrossRef Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A. 2003;100:8933–8.CrossRef
21.
go back to reference Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.CrossRef Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463–75.CrossRef
22.
go back to reference Hubbard SR. EGF receptor activation: push comes to shove. Cell. 2006;125:1029–31.CrossRef Hubbard SR. EGF receptor activation: push comes to shove. Cell. 2006;125:1029–31.CrossRef
23.
go back to reference Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14:3550–8.CrossRef Soltoff SP, Carraway KL 3rd, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol. 1994;14:3550–8.CrossRef
24.
go back to reference Erickson SL, O'Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124:4999–5011.PubMed Erickson SL, O'Shea KS, Ghaboosi N, Loverro L, Frantz G, Bauer M, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124:4999–5011.PubMed
25.
go back to reference Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Koziorowski M. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 1997;389:725–30.CrossRef Riethmacher D, Sonnenberg-Riethmacher E, Brinkmann V, Koziorowski M. Severe neuropathies in mice with targeted mutations in the ErbB3 receptor. Nature. 1997;389:725–30.CrossRef
27.
go back to reference Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J. Diagnosis and management of silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol. 2017;13:105–24.CrossRef Wakeling EL, Brioude F, Lokulo-Sodipe O, O'Connell SM, Salem J, Bliek J. Diagnosis and management of silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol. 2017;13:105–24.CrossRef
Metadata
Title
Biallelic ERBB3 loss-of-function variants are associated with a novel multisystem syndrome without congenital contracture
Authors
Niu Li
Yufei Xu
Yi Zhang
Guoqiang Li
Tingting Yu
Ruen Yao
YunFang Zhou
Yiping Shen
Lei Yin
Xiumin Wang
Jian Wang
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2019
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-019-1241-z

Other articles of this Issue 1/2019

Orphanet Journal of Rare Diseases 1/2019 Go to the issue